PD-1 as a potential target in cancer therapy

Por McDermott, David F, Atkins, Michael B
Publicado em 2013

Management of metastatic renal cell carcinoma in patients with poor prognosis

Por Bullock, Andrea, McDermott, David F, Atkins, Michael B
Publicado em 2010

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Por Mahoney, Kathleen M., Freeman, Gordon J., McDermott, David F.
Publicado no Clin Ther (2015)

Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreas

Por Demirjian, Aram N, Vollmer, Charles M, McDermott, David F, Mullen, John T, Atkins, Michael B, Callery, Mark P
Publicado em 2009

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

Por Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Publicado em 2013

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado em 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado em 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Por Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Publicado no J Pers Med (2014)

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

Por Schoenfeld, Jonathan D., Mahadevan, Anand, Floyd, Scott R., Dyer, Michael A., Catalano, Paul J., Alexander, Brian M., McDermott, David F., Kaplan, Irving D.
Publicado no J Immunother Cancer (2015)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Por Atkins, Michael B, Gupta, Shilpa, Choueiri, Toni K, McDermott, David F, Puzanov, Igor, Tarazi, Jamal, Keefe, Stephen, Rosbrook, Brad, Chakrabarti, Debasis, Plimack, Elizabeth R
Publicado no J Immunother Cancer (2015)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and...

Por Flaherty, Keith T., Manola, Judith B., Pins, Michael, McDermott, David F., Atkins, Michael B., Dutcher, Janice J., George, Daniel J., Margolin, Kim A., DiPaola, Robert S.
Publicado no J Clin Oncol (2015)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use...

Por Wong, Michael KK, Morse, Michael A, McDermott, David F, Clark, Joseph I, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado no J Immunother Cancer (2015)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Por Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado no J Immunother Cancer (2015)

Sargramostim plus Ipilimumab vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial

Por Hodi, F. Stephen, Lee, Sandra, McDermott, David F., Rao, Uma N., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip, Puzanov, Igor, Shin, Donghoon, Kirkwood, John M.
Publicado no JAMA (2014)

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Por Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Publicado no Oncologist (2015)

Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma

Por Choueiri, Toni K., Lim, Zita Dubauskas, Hirsch, Michelle S., Tamboli, Pheroze, Jonasch, Eric, McDermott, David F., Cin, Paola Dal, Corn, Paul, Vaishampayan, Ulka, Heng, Daniel Y.C., Tannir, Nizar M.
Publicado no Cancer (2010)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

Por Chandar, Ashwin, Silk, Ann W, Clark, Joseph I, Daniels, Gregory A, McDermott, David F, Morse, Michael, Wong, Michael KK, Stein, Mark, Mehnert, Janice, Danish, Shabbar, Aung, Sandra, Kaufman, Howard L
Publicado no J Immunother Cancer (2015)

Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases

Por Amaravadi, Ravi K., Schuchter, Lynn M., McDermott, David F., Kramer, Amy, Giles, Lydia, Gramlich, Kristi, Carberry, Mary, Troxel, Andrea B., Letrero, Richard, Nathanson, Katherine L., Atkins, Michael B., O’Dwyer, Peter J., Flaherty, Keith T.
Publicado em 2009

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

Por Kim, Kevin B., Sosman, Jeffrey A., Fruehauf, John P., Linette, Gerald P., Markovic, Svetomir N., McDermott, David F., Weber, Jeffrey S., Nguyen, Hoa, Cheverton, Peter, Chen, Daniel, Peterson, Amy C., Carson, William E., O'Day, Steven J.
Publicado no J Clin Oncol (2012)

Differential expression of PD-L1 between primary and metastatic sites in clear cell Renal Cell Carcinoma

Por Callea, Marcella, Albiges, Laurence, Gupta, Mamta, Cheng, Su-Chun, Genega, Elizabeth M., Fay, André P., Song, Jiaxi, Carvo, Ingrid, Bhatt, Rupal S., Atkins, Michael B., Hodi, F. Stephen, Choueiri, Toni K., McDermott, David F., Freeman, Gordon J., Signoretti, Sabina
Publicado no Cancer Immunol Res (2015)